Trials / Withdrawn
WithdrawnNCT00811863
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Guerbet · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to prospectively monitor the incidence of adverse drug reactions, specifically NSF during routine use of gadoversetamide in a large number of patients with moderate renal insufficiency (eGFR 30-59) and severe renal insufficiency or end-stage renal disease requiring dialysis (eGFR \<30).
Conditions
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2012-05-17
- Completion
- 2012-05-17
- First posted
- 2008-12-19
- Last updated
- 2017-08-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00811863. Inclusion in this directory is not an endorsement.